Concepedia

Siyang Peng

SP

Statistics

Publications

7

Citations

367

H-Index

7

Active since

2010

Affiliations

Boehringer Ingelheim (Germany)(Current)

Ithaka Harbors

Siyang Peng is an author at Boehringer Ingelheim (Germany) specializing in cost-effectiveness analysis, pharmacoeconomics, and pharmacy.

ORCID

Publications per year

2010–2015

7

Publications

7

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

Stuart Connolly, Siyang Peng, John E. Linnehan et al. · Thrombosis and Haemostasis · 2011 · 204 citations

, , +17

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada

Michael Sharma, Carole Bradley-Kennedy, Andreas Clemens et al. · Thrombosis and Haemostasis · 2012 · 56 citations

, , +17

Economic Analysis of Decitabine Versus Best Supportive Care in the Treatment of Intermediate- and High-Risk Myelodysplastic Syndromes From a US Payer Perspective

Feng Pan, Siyang Peng, Rachael Fleurence et al. · Clinical Therapeutics · 2010 · 31 citations

, , +10

Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups

Andreas Clemens, Siyang Peng, Sarah Brand et al. · The American Journal of Cardiology · 2014 · 23 citations · Full text

, , +17

Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States

Siyang Peng, Ali Tafazzoli, Emily Dorman et al. · Journal of Medical Economics · 2015 · 21 citations · Full text

, , +17

1–5 of 7